Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology | Musculoskeletal | Family Medicine
Clinical Trials: Multiple Myeloma
A listing of clinical trials currently looking for volunteers to enroll in Multiple Myeloma studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Birmingham : University of Alabama at Birmingham
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Birmingham : Birmingham Hematology & Oncology Associates Llc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Huntsville : Clearview Cancer Institute
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Huntsville : Clearview Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Huntsville : The Cancer Center of Huntsville
Connect® MM- The Multiple Myeloma Disease Registry
Tuscaloosa : DCH Health System
Connect® MM- The Multiple Myeloma Disease Registry
Alaska
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Arizona
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Phoenix : Arizona Oncology Associates
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Scottsdale :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Scottsdale : Mayo Clinic Arizona
Dose-escalation Study of Oral CX-4945
Scottsdale : Mayo Clinic in Arizona
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Scottsdale : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Tucson : US Oncology - Arizona Oncology Associates - Rudasill
Connect® MM- The Multiple Myeloma Disease Registry
Tucson : Acrc/Arizona Clinical Research Center, Inc.
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Arkansas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Fort Smith : St. Edward Mercy Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Hot Springs : Genesis Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Jonesboro : Clopton Clinic Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Little Rock : University of Arkansas for Medical Sciences
Compassionate Use Study of Carfilzomib
Little Rock : Little Rock Hematology Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Little Rock : The University of Arkansas for Medical Sciences
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Little Rock : University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Rogers : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
California
Duarte : City of Hope
A Phase I Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (Protocol ARRAY-520-111)
Duarte : City of Hope
A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma
Duarte : City of Hope
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
Duarte : City of Hope
An Open Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF-4539A in Patients with Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Duarte : City of Hope
BMT CTN 0702: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Duarte : City of Hope
Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients Undergoing Hematopoetic Cell Transplantation (HCT)
Duarte : City of Hope
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with High Risk Multiple Myeloma
Duarte : City of Hope
SWOG S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zolecronic Acid Treatment
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Anaheim : Pacific Cancer Medical Center Incorporated
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Anaheim : Pacific Cancer Medical Center, Inc.
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Anaheim : Pacific Cancer Medical Center, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Anaheim : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Bakersfield : Comprehensive Blood and Cancer Center
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Berkeley : Alta Bates Summit Comprehensive Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Berkeley : Alta Bates Summit Comprehensive Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Burbank : Providence Saint Joseph Medical Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Campbell : Southbay Oncology Hematology Partners
Connect® MM- The Multiple Myeloma Disease Registry
Corona : Compassionate Cancer Care Medical Group (Corona)
Connect® MM- The Multiple Myeloma Disease Registry
Corona : Compassionate Cancer Care Medical Group Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Corona : Compassionate Cancer Care Medical Group, Inc Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Duarte :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope Hospital
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Duarte : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Encinitas : Pacific Oncology and Hematology
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Escondido : Southwest Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Fountain Valley : Compassionate Cancer Care Medical Group (Fountain Valley)
Connect® MM- The Multiple Myeloma Disease Registry
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Fullerton : Virginia K. Crosson Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Greenbrae : Marin Cancer Care, Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
La Jolla : Moores UCSD Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
La Jolla : University of California, San Diego
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Lancaster : TORI - Antelope Valley Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
LaVerne :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Long Beach : Long Beach Memorial
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Los Angeles : UCLA
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Los Angeles : USC/Norris Comprehensive Cancer Center
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Los Angeles : Division Of Hematology & Oncology Ctr. For Health Sciences
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Los Angeles : Ucla Department Of Medicine Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Los Angeles : Cedars-Sinai Medical Center-Samuel Oschin Comprehensive Cancer Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Los Angeles : UCLA Neuro-Oncology Program
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Los Angeles : West Los Angeles VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Monterey : Monterey Bay Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Newport Beach : Michael J. Schlutz, M.D., Inc
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Northridge : TORI - North Valley Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Oakland : Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Orange : Medical Oncology Care Associates
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Orange : Medical Oncology Care Associates Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Palm Springs : Comprehensive Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Palo Alto : Stanford Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Pleasant Hill : Bay Area Cancer Research Group, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Pleasant Hill : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pomona : New Hope Cancer & Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Riverside : Campassionate Cancer Care Medical Group (Riverside)
Connect® MM- The Multiple Myeloma Disease Registry
Roseville : Capitol Hematology Oncology Medical Group - Sutter Roseville
Connect® MM- The Multiple Myeloma Disease Registry
Salinas : Pacific Cancer Care
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
San Diego : Sharp Clinical Oncology Research
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
San Diego : Sharp Clinical Oncology Research
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
San Diego : Sharp Clinical Oncology Research Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
San Francisco :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
San Francisco : University of California at San Francisco
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
San Francisco : University of California at San Francisco
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
San Pablo : Alta Bates Comprehensive Cancer Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
San Pablo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Santa Barbara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Santa Barbara : Cancer Center of Santa Barbara
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Santa Barbara : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Santa Maria : TORI - Central Coast Medical Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Santa Maria : Central Coast Medical Oncology
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Santa Maria : Central Coast Medical Oncology
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Santa Rosa : Redwood Regional Medical Group, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
Stanford : Stanford University School of Medicine
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stockton : Stockton Hematology Oncology Medical Group, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
West Hollywood : James R Berenson, MD, Inc.
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
West Hollywood : James R. Berenson, MD, Inc.
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
West Hollywood : Berenson Oncology
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
West Hollywood : Institute for Myeloma and Bone Cancer Research
Connect® MM- The Multiple Myeloma Disease Registry
West Hollywood : James R. Berenson MD, Incorporated
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
West Hollywood : James R. Berenson M.D., Inc.
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
West Hollywood : James R. Berenson, MD, Inc.
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
West Hollywood : James R. berenson, M.D., Inc.
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Colorado
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Aurora :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Aurora : US Oncology- Rocky Mountain Cancer Center-Aurora
Connect® MM- The Multiple Myeloma Disease Registry
Boulder :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Boulder : US Oncology - Rocky Mountain Cancer Center-Boulder
Connect® MM- The Multiple Myeloma Disease Registry
Colorado Springs :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Colorado Springs : US Oncology - Rocky Mountain Cancer Center-Colorado Springs
Connect® MM- The Multiple Myeloma Disease Registry
Colorado Springs : US Oncology- Rocky Mountain Cancer Center at the Pavillion
Connect® MM- The Multiple Myeloma Disease Registry
Denver : RMCC
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Denver :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Denver : Rocky Mountain Cancer Centers - Denver
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Denver : US Oncology - Rocky Mountain Cancer Center-Midtown
Connect® MM- The Multiple Myeloma Disease Registry
Denver : US Oncology - Rocky Mountain Cancer Center-Rose
Connect® MM- The Multiple Myeloma Disease Registry
Denver : Rocky Mountain Cancer Centers - Denver Midtown
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Denver : Colorado Blood Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Denver : Colorado Blood Cancer Institute
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Fort Collins : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Grand Junction : TORI - St. Mary's Advanced Medical Pavilion
Connect® MM- The Multiple Myeloma Disease Registry
Lakewood :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Lakewood : US Oncology - Rocky Mountain Cancer Center-Lakewood
Connect® MM- The Multiple Myeloma Disease Registry
Littleton :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Littleton : US Oncology - Rocky Mountain Cancer Center-Littleton
Connect® MM- The Multiple Myeloma Disease Registry
Lone Tree : US Oncology - Rocky Mountain Cancer Center-Sky Ridge
Connect® MM- The Multiple Myeloma Disease Registry
Longmont :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Longmont : US Oncology - Rocky Mountain Cancer Center-Longmont
Connect® MM- The Multiple Myeloma Disease Registry
Loveland : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Parker :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Parker : US Oncology - Rocky Mountain Cancer Center-Parker
Connect® MM- The Multiple Myeloma Disease Registry
Pueblo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Thornton :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Thornton : US Oncology - Rocky Mountain Cancer Center-Thornton
Connect® MM- The Multiple Myeloma Disease Registry
Connecticut
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Fairfield : Medical Specialists of Fairfield
Connect® MM- The Multiple Myeloma Disease Registry
Manchester : Medical Oncology and Blood Disorders, LLP
Connect® MM- The Multiple Myeloma Disease Registry
New Britain : Hospital of Central Connecticut
Connect® MM- The Multiple Myeloma Disease Registry
New Haven : Yale University School Of Medicine
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
New Haven : Yale University School of Medicine
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
New Haven : Yale University
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
New Haven : Yale University School Of Medicine
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Stamford : Hematology Oncology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Delaware
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Newark : Delaware Clinical & Laboratory Physicians, PA
Connect® MM- The Multiple Myeloma Disease Registry
District of Columbia
Washington : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Washington : Georgetown Lombardi Comprehensive Cancer Center
Phase I Study of CS-7017 and Bexarotene
Washington : Washington Cancer Institute At Washington Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Florida
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Boynton Beach : Collaborative Research Group
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : University Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Boynton Beach : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Brooksville : Cancer Care Centers Of Florida
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Coral Springs : Flora Research Associates
Connect® MM- The Multiple Myeloma Disease Registry
Deerfield Beach : Archbold Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Deerfield Beach : Flora Research Associates
Connect® MM- The Multiple Myeloma Disease Registry
Fort Myers : Florida Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ft. Lauderdale : Broward Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Gainesville : Florida Cancer Specialists & Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Hollywood : Memorial Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Hollywood : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Hudson : US Oncology - Florida Cancer Institute - New Hope-Hudson
Connect® MM- The Multiple Myeloma Disease Registry
Jacksonville :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Jacksonville : Integrated Community Oncology Network, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Jacksonville : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Jacksonville : Integrated Community Oncology Network
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Jacksonville : Integrated Community Oncology Network Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Lake City : Cancer Care of North Florida
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lakeland : Watson Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Lecanto : Cancer and Blood Disease Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lecanto : Cancer & Blood Disease Center
Connect® MM- The Multiple Myeloma Disease Registry
Melbourne : Medical Associate of Brevard (MAB) Oncology/Hematology
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
New Port Richey : Pasco Hernando Oncology Associates (Kumar)
Connect® MM- The Multiple Myeloma Disease Registry
New Port Richey : US Oncology - Florida Cancer Institute - New Hope-New Port Richey
Connect® MM- The Multiple Myeloma Disease Registry
New Port Richey : Cancer Care Centers Of Florida
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ocala : Ocala Oncology Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Orlando : MD Anderson Orlando
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Pensacola : Sacred Heart Medical Oncology Group
Connect® MM- The Multiple Myeloma Disease Registry
Rockledge : Cancer Care Centers of Brevard
Connect® MM- The Multiple Myeloma Disease Registry
St. Petersburg : Florida Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tampa : H. Lee Moffitt Cancer Center & Research Institute
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Tampa : H. Lee Moffitt Cancer Center
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Tampa : Investigational Site Number 840001
Phase 1 SAR650984 Combination With Lenalidomide
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Tampa : H. Lee Moffitt Cancer Center
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Tampa : Moffitt Cancer Center & Research Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The Villages : Florida Hospital Waterman-Lake County Oncology & Hematology
Connect® MM- The Multiple Myeloma Disease Registry
West Palm Beach : Palm Beach Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
West Palm Beach : Palm Beach Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
West Palm Beach : Palm Beach Cancer Institute Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Weston : Cleveland Clinic Florida
Connect® MM- The Multiple Myeloma Disease Registry
Georgia
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Albany : Phoebe Putney Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Emory
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Atlanta : Emory University Winship Cancer Institute
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Atlanta : Emory University, Winship Cancer Institute
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Atlanta : Emory University, Winship Cancer Institute
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Atlanta : Georgia Cancer Specialists
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Atlanta : Emory University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Atlanta : Georgia Cancer Specialists
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Peachtree Hematology-Oncology Consultants
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Emory University Winship Cancer Institute
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Atlanta : Emory University Winship Cancer
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Atlanta : Winship Cancer Institute, Emory University
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Atlanta : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Atlanta : Winship Cancer Institute
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Atlanta : Winship Cancer Institute, Emory University
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Atlanta : Emory University Winship Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Atlanta : Winship Cancer Institute, Emory University
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Atlanta : Emory University
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Atlanta : Emory University
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Atlanta : Emory University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Marietta : Northwest Georgia Oncology Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Savannah : Summit Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Savannah : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hawaii
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Honolulu : Straub Clinic and Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Idaho
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Illinois
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland, PC
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : John H. Stroger Jr. Hospital of Cook County
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Chicago : University of Chicago
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Chicago :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Chicago :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Chicago : Rush University Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Chicago : John H. Stroger, Jr. Hospital of Cook County
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : Rush University Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : Univeristy of Chicago Medical Center, Section of Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : University of IL at Chicago
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Chicago : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Chicago : University of Chicago, School of Medicine
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Chicago : The University Of Chicago
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Chicago : The University of Chicago
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Chicago : University Of Chicago Medical Center Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Decatur : Cancer Care Specialists Of Central Illinois Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Elmhurst : Elmhurst Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Evanston : Northshore University Health System
Connect® MM- The Multiple Myeloma Disease Registry
Galesburg : Medical and Surgical Specialists
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Harvey : Ingalls Cancer Research Center
Connect® MM- The Multiple Myeloma Disease Registry
Hines : Edward Hines Jr VA Hospital
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Joliet : Joliet Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Joliet : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Moline : Medical Arts Associates, Ltd
Connect® MM- The Multiple Myeloma Disease Registry
Niles :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Niles : Oncology Specialists, S.C.
Connect® MM- The Multiple Myeloma Disease Registry
Park Ridge : Oncology Specialists, S.C. Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Peoria : Illinois Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Skokie : Orchard Research
Connect® MM- The Multiple Myeloma Disease Registry
Skokie : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Urbana : Carle Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Urbana : Carle Cancer Center Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Winfield :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Zion : Cancer Centers of America
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Indiana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anderson : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Beech Grove : Indiana Blood and Marrow Transplant, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Beech Grove : St. Francis Cancer Research
Connect® MM- The Multiple Myeloma Disease Registry
Fort Wayne : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goshen : IU Health Goshen Hospital
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Goshen : Center for Cancer Care @ Goshen Health Systems
Connect® MM- The Multiple Myeloma Disease Registry
Indianapolis : Indiana University Simon Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Indianapolis : IU Simon Cancer Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Indianapolis : Community Regional Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : IU Health Central Indiana Cancer Centers
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Indianapolis : Indiana University Cancer Center Clinical Research Office
Connect® MM- The Multiple Myeloma Disease Registry
Indianapolis : IU Simon Cancer Center
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Indianapolis : Hematology-Oncology of Indiana, PC
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Indianapolis : Investigative Clinical Research Of Indiana, Llc Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Indianapolis : Franciscan St. Francis Health
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Mishawaka : Michiana Hematology Oncology, P.C.
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Munster : Cancer Research-Munster
Connect® MM- The Multiple Myeloma Disease Registry
New Albany : Cancer Care Center Inc.
Connect® MM- The Multiple Myeloma Disease Registry
Newburgh : Oncology Hematology Associates of SW IN
Connect® MM- The Multiple Myeloma Disease Registry
South Bend : Northern Indiana Cancer Research Consortium
Connect® MM- The Multiple Myeloma Disease Registry
Iowa
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Ames : McFarland Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Ames : McFarland Clinic
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Bettendorf : Hematology Oncology Associates of the Quad Cities
Connect® MM- The Multiple Myeloma Disease Registry
Cedar Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Cedar Rapids : Iowa Blood and Cancer Care of PCI
Connect® MM- The Multiple Myeloma Disease Registry
Iowa City : University of Iowa Hospitals
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Iowa City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Iowa City : University Of Iowa Hospitals And Clinics
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Sioux City : Siouxland Hematology-Oncology Associates, LLP
Connect® MM- The Multiple Myeloma Disease Registry
Sioux City : Siouxland Hematology Oncology Associates
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Waterloo : Cedar Valley Medical Specialists
Connect® MM- The Multiple Myeloma Disease Registry
Waterloo : Covenant Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Kansas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Fairway : University of Kansas Medical Center
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Wichita : Cancer Center of Kansas, PA
Connect® MM- The Multiple Myeloma Disease Registry
Kentucky
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Ashland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Hazard : Kentucky Cancer Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Hazard : Kentucky Cancer Clinic Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Louisville : Baptist Hospital East
Connect® MM- The Multiple Myeloma Disease Registry
Paducah : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Louisiana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Baton Rouge : Mary Bird Perkins Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lafayette : Cancer Center Of Acadiana At Lafayette General
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Lafayette : Cancer Center Of Acadiana Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Maine
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Scarborough : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maryland
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Baltimore :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Baltimore : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Baltimore : Sidney Kimmel Cancer Center Johns Hopkins Hospital
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Baltimore : University of Maryland Medical Center - M & S Greenebaum Cancer Center
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Baltimore : University of Maryland Greenebaum Cancer Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Baltimore : Greater Baltimore Medical Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Baltimore : Harry & Jeanette Weinberg Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Baltimore : Greenebaum Cancer Center, University of Maryland
Redirected Auto T Cells for Advanced Myeloma
Baltimore : Greater Baltimore Medical Center Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Baltimore : Johns Hopkins University
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Bethesda :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Bethesda : Center for Cancer & Blood Disorders, PC
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Bethesda : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Lenalidomide Maintenance Therapy for Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Bethesda : Center for Cancer and Blood Disorders
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Bethesda : National Capital Clinical Research Consortium
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Bethesda : Center for Cancer and Blood Disorders
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Columbia :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Rockville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Rockville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Rockville : Associates in Oncology/Hematology, P.C.
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Westminster : Alliance Hematology Oncology, PA
Connect® MM- The Multiple Myeloma Disease Registry
Westminster : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Massachusetts
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Boston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Boston :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Boston : Dana-Farber Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Boston : Dana Farber Cancer Institute
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Boston : Dana-Farber Cancer Institute
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Boston : Dana-Farber Cancer Institute
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Boston : Beth Israel Deaconess Medical Center
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Dana Faber Cancer Institute
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Massachusetts General Hospital
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Tufts Medical Center
Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Beth Israel Deaconess Medical Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Massachusetts General Hospital
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Beth Israel Deaconess Medical Center
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Massachusetts General Hospital
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Dana-Farber Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Boston : Tufts Medical Center
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Boston : Massachusetts General Hospital
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Boston : Massachusetts General Hospital
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Boston : Beth Israel Deaconess Medical Center
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Hyannis : Capecod Hospital/Davenport Mugar Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Jamaica Plain : VA Boston Healthcare System
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Worcester : Fallon Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Worcester : Reliant Medical Group, Inc Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Michigan
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Ann Arbor : University of Michigan Comprehensive Cancer Center Main Office
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Ann Arbor : University of Michigan
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Ann Arbor : University Of Michigan
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ann Arbor : University of Michigan Comprehensive Cancer Center
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Bay City : Michigan State University/Bay Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Detroit : Karmanos Cancer Institute
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Detroit : Karmanos Cancer Institute
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Detroit :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Detroit :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Detroit : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Detroit : Henry Ford Health System
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Detroit : Barbara Ann Karmanos Cancer Institute
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Detroit : Karmanos Cancer Institute
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Flint : Genesys Hurley Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Flint : Michigan State University/McLaren Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Grand Rapids : Grand Rapids Clinical Oncology Program
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Kalamazoo : West Michigan Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lansing : Michigan State University/Breslin Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lapeer : Michigan State University/Lapeer Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Mount Clemens : Michigan State University/Mount Clemens Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Novi : Newland Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Owosso : Michigan State University/Memorial Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Southfield : Newland Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Wyoming : Metro Health Cancer Care
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Minnesota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Duluth : Duluth Clinic Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Minneapolis : Minnesota Oncology Hematology P.A.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Minneapolis : University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Rochester : Mayo Clinic - Rochester Mayo 3
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Rochester : Mayo Clinic
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Rochester : The Mayo Clinic
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
St. Louis Park : Park Nicollet Institute - Louisiana Ave.
Connect® MM- The Multiple Myeloma Disease Registry
Mississippi
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Jackson : Jackson Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Missouri
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Chesterfield : St. Louis Cancer Care, LLP
Connect® MM- The Multiple Myeloma Disease Registry
Jefferson City : Capitol Comprehensive Cancer Care Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Jefferson City : Columbia Comprehensive Cancer Care Clinic
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Kansas City : Kansas City Cancer Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Kansas City : Kansas City VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Springfield : St. John's Medical Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Springfield : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Springfield : Mercy Medical Research Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Springfield : Mercy Medical Research Institute Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
St Louis :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
St Louis : Washington University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
St Louis : Investigational Site Number 840002
Phase 1 SAR650984 Combination With Lenalidomide
St. Joseph : St. Joseph Oncology
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Washington University School of Medicine
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
St. Louis : Washington University School Of Medicine
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
St. Louis : Washington University School Of Medicine
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
St. Louis : Hematology Oncology Consultants, Inc
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : St. John's Mercy Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : University Hematology Oncology, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Washington University in St. Louis, Division of Oncology, Section of Bone Marrow Transplantation & Leukemia
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Washington University School of Medicine Division of Oncology
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
St. Louis : Washington University School Of Medicine
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
St. Louis : Washington University School Of Medicine Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
St. Louis : Washington University School Of Medicine
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Montana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Billings : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Missoula : Montana Cancer Institute Foundation
Connect® MM- The Multiple Myeloma Disease Registry
Nebraska
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Lincoln : Nebraska Hematology Oncology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC
Connect® MM- The Multiple Myeloma Disease Registry
Lincoln : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Omaha : University of Nebraska Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Omaha : Missouri Valley Cancer Consortium
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Nevada
New Hampshire
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Lebanon : Dartmouth Hitchcock Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lebanon : Dartmouth Hitchcock Medical Center
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Portsmouth : Portsmouth Regional Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
New Jersey
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Belleville : Essex Oncology of North Jersey, PA
Connect® MM- The Multiple Myeloma Disease Registry
Cherry Hill : The Center for Cancer and Hematologic Disease
Connect® MM- The Multiple Myeloma Disease Registry
Englewood : Drs. Forte, Schleider, Attas & Condemi, PA
Connect® MM- The Multiple Myeloma Disease Registry
Hackensack : HUMC
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Hackensack : Hackensack University Medical Center
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center
Escalating Doses Thalidomide+Bortezomib+HIgh Dose Melphalan for Auto PBSC Transplant in Patients With Multiple Myeloma
Hackensack : Hackensack University Medical Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Hackensack : John Theurer Cancer Center at Hackensack University
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Hackensack : Hackensack University Medical Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Hackensack : Hackensack University Medical Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Hackensack : Hackensack University Medical Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Hackensack : John Theurer Cancer Center
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Hackensack : John Theurer Cancer Center-Hackensack University Medical Center
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Hackensack : John Theurer Cancer Center at Hackensack University
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Hackensack : John Theurer Cancer Center - Hackensack University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Morristown :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Morristown : Hematology-Oncology Associates of Northern NJ dba Carol G. Simon
Connect® MM- The Multiple Myeloma Disease Registry
Somerville : Steeplechase Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
New Mexico
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Phase 2 Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Multiple Myeloma Undergoing Limited Re-infusion of CD34+ Cells
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Albany : New York Oncology Hematology, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Albany : US Oncology - Albany Medical Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Albany : US Oncology - New York Oncology Hematology, PC-Albany
Connect® MM- The Multiple Myeloma Disease Registry
Amsterdam : US Oncology - Amsterdam Community Cancer Program
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Bronx River Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Eastchester Center for Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Montefiore Medical Center
Study of Intravenous Busulfan in Combination With Melphalan and Bortezomib in Patients With Multiple Myeloma
Buffalo : Jonah Cancer Care Center & ECMC
Connect® MM- The Multiple Myeloma Disease Registry
Buffalo : Roswell Park Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Great Neck :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Hudson : US Oncology - Cavell Cancer Treatment Program
Connect® MM- The Multiple Myeloma Disease Registry
Johnson City : Broome Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Lake Success : Arena Oncology Associates, PC
Connect® MM- The Multiple Myeloma Disease Registry
Latham : US Oncology - New York Oncology Hematology, PC-Latham
Connect® MM- The Multiple Myeloma Disease Registry
Long Island : Stony Brook
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
New Hyde Park : Long Island Jewish medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Columbia University
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
New York : Mount Sinai Medical Center
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
New York :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
New York :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
New York : NYU Cancer Institute
A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma
New York : Memorial Sloan-Kettering Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Weill Medical College of Cornell
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Memorial Sloan Kettering Cancer Center
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
New York : New York University Langone Medical Center
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
New York : Memorial Sloan-Kettering Cancer Center
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
New York : Memorial Sloan-Kettering Cancer Center
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
New York : Memorial Sloane Kettering Cancer Center
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
New York : Weill Cornell Medicial College
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
New York : Memorial Sloan-Kettering Cancer Centre
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
New York : Memorial Sloan-Kettering Cancer Center
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
New York : Weill Cornell Medical College
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
New York : Memorial Sloan-Kettering Cancer Center
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
New York : Mount Sinai School of Medicine
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
New York : Memorial Sloan-Kettering Cancer Center
Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
New York : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
New York :
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
New York : Weill Medical College of Cornell University
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
New York : Mount Sinai School of Medicine
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
New York : St. Luke'S-Roosevelt Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
New York : St. Luke'S Roosevelt Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
New York : Memorial Sloan Kettering Cancer Center
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
New York : The Mount Sinai School of Medicine
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
New York : Memorial Sloan Kettering Cancer Ctr
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
New York : Mt. Sinai Medical Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
New York : Weill Cornell Medical College
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
New York : Mount Sinai School of Medicine
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
New York : Memorial Sloan Kettering Cancer Center
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
New York : NYU Cancer Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
New York : Weill Cornell Medical College
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
New York City : Cornell
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Rexford : US Oncology - New York Oncology Hematology, PC-Rexford
Connect® MM- The Multiple Myeloma Disease Registry
Stony Brook : Stony Brook University Hospital
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Stony Brook : Stony Brook University Medical Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Syracuse : SUNY Upstate Medical University - Adult Program
Connect® MM- The Multiple Myeloma Disease Registry
Troy : US Oncology - Troy Cancer Treatment Program
Connect® MM- The Multiple Myeloma Disease Registry
North Carolina
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Cary : US Oncology - Cancer Centers of North Carolina - Cary
Connect® MM- The Multiple Myeloma Disease Registry
Chapel Hill : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Chapel Hill : UNC Lineberger Comprehensive Cancer Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Chapel Hill : University of North Carolina at Chapel Hill
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Chapel Hill : UNC Lineberger Comprehensive Cancer Center
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Charlotte : Carolinas Medical Center
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Charlotte : Mecklenburg Medical Group
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Durham : Duke University Medical Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Durham : DUMC Division of Cellular Therapy/ABMT
Connect® MM- The Multiple Myeloma Disease Registry
Durham : Duke University
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Durham : Duke University Medical Center
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Fayetteville : Blood and Cancer Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Fayetteville : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goldsboro : Southeastern Medical Oncology Center
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Hickory : Carolina Oncology Specialists, PA
Connect® MM- The Multiple Myeloma Disease Registry
High Point : Emerywood Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
High Point : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Raleigh : US Oncology - Cancer Centers of North Carolina - Falls
Connect® MM- The Multiple Myeloma Disease Registry
Winston-Salem : Piedmont Hematology Oncology Associates, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
North Dakota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Bismarck : Mid Dakota Clinic, Pc
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bismarck : Legacy Pharma Research
Connect® MM- The Multiple Myeloma Disease Registry
Bismarck : Med Center One
Connect® MM- The Multiple Myeloma Disease Registry
Bismarck : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fargo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Fargo : Roger Maris Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Ohio
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Akron : Summa Health System - Cancer Research Office
Connect® MM- The Multiple Myeloma Disease Registry
Canton : Gabrail Cancer Center Research
Connect® MM- The Multiple Myeloma Disease Registry
Canton : Gabrail Cancer Center Research
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Canton : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cincinnati : Christ Hospital Cancer Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Cincinnati : Oncology Hematology Care Inc.
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Cleveland : University Hospitals Seidman Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Cleveland : University Hospitals Case Medical Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Cleveland : Cleveland VA Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Cleveland : Cleveland Clinic
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Cleveland : Case Western Reserve University, University Hospitals of Cleveland
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cleveland : Cleveland Clinic, Taussig Cancer Institute
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Columbus : OSU
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Columbus : The Ohio State University Medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Columbus : Mid Ohio Oncology/Hematology, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Columbus : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Columbus : Ohio State University
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Columbus : Benson, Md, Don
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Columbus : Ohio State University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Elyria : Hematology Oncology Center, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Kettering :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Wooster : Lawrence M. Stallings MD LTD dba Trilogy Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Oklahoma
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Tulsa : Cancer Care Associates
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Oregon
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Eugene : Willamette Valley Cancer and Research / USOR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene
Connect® MM- The Multiple Myeloma Disease Registry
Portland : Oregon Health & Science University
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Portland :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Portland : Oregon Health Science University
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Springfield : Willamette Valley Cancer Institute and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield
Connect® MM- The Multiple Myeloma Disease Registry
Springfield :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Tualatin :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tualatin : Northwest Cancer Specialists, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Pennsylvania
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Bethlehem : Oncology Hematology of Lehigh Valley
Connect® MM- The Multiple Myeloma Disease Registry
Danville : Geisinger Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Drexel Hill : Consultants in Medical Oncology and Hematology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Harrisburg : Andrews and Patel Associates
Connect® MM- The Multiple Myeloma Disease Registry
Kingston : US Oncology - Medical Oncology Associates (Nahar)
Connect® MM- The Multiple Myeloma Disease Registry
Kittanning :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Lancaster : Lancaster Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Philadelphi : University Hospital of Pennsylvania
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia : University of Pennsylvania Abramson Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Philadelphia : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Philadelphia : Fox Chase Cancer Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Philadelphia : Abramson Cancer Center of the University of Pennsylvania
Redirected Auto T Cells for Advanced Myeloma
Philadelphia : University of Pennsylvania
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Philadelphia : Hospital of the University of Pennsylvania
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Pittsburgh : UPCI Hillman Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Pittsburgh : The Western Pennsylvania Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Pittsburgh : Pittsburgh VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Reading : Berks Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Scranton : Scranton Hematology Oncology
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
West Reading : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
West Reading : Reading Hospital and Medical Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Rhode Island
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Cranston : Hematology & Oncology Associates of Rhode Island
Connect® MM- The Multiple Myeloma Disease Registry
South Carolina
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Charleston : MUSC Hollings Cancer Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Charleston : Medical University of South Carolina Hollings Cancer Center
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Charleston : Charleston Hematology Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Charleston : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Charleston : Charleston Hematology Oncology Associates, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Columbia : South Carolina Oncology Associates
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Easley : US Oncology - Cancer Centers of the Carolinas - Easley
Connect® MM- The Multiple Myeloma Disease Registry
Greenville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Greenville : Saint Francis Hospital
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - Eastside
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : Cancer Center of the Carolinas
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Greenville :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Hilton Head Island : SC Cancer Specialists, PA
Connect® MM- The Multiple Myeloma Disease Registry
Seneca : US Oncology - Cancer Center of the Carolinas - Seneca
Connect® MM- The Multiple Myeloma Disease Registry
Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg
Connect® MM- The Multiple Myeloma Disease Registry
South Dakota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Sioux Falls : Avera Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Sioux Falls : Sanford Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Tennessee
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Chattanooga : Chattanooga Oncology Hematology Associates
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Collierville : Family Cancer Center, PLLC
Connect® MM- The Multiple Myeloma Disease Registry
Germantown : Jones Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Kingsport :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Knoxville : Tennessee Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Memphis : Family Cancer Center Foundation, Inc.
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Nashville :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Nashville :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Nashville : Sarah Cannon Research Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Nashville : SCRI
Connect® MM- The Multiple Myeloma Disease Registry
Nashville : Tennessee Oncology, PLLC
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Nashville : The Vanderbilt Clinic
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Nashville : Tennessee Oncology
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Nashville : Tennessee Oncology, Pllc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Nashville : Sarah Cannon Research Institute
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Nashville : Sarah Cannon Research Institute
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Nashville : Sarah Cannon Research Institute Tennessee Oncology Drug Development Unit
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Nashville : Tennessee Oncology, Pllc
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Nashville : Sarah Cannon Research Institute
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Nashville : Tennessee Oncology
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Nashville : Sarah Cannon Research Institute (SCRI) Drug Development Unit
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Nashville : Sarah Cannon Research Institute (SCRI)
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Texas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Abilene : US Oncology - Texas Cancer Center - Abilene (South)
Connect® MM- The Multiple Myeloma Disease Registry
Amarillo : US Oncology - Texas Oncology, PA - Amarillo
Connect® MM- The Multiple Myeloma Disease Registry
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Arlington : US Oncology - Texas Oncology - Arlington South
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - South Austin Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Austin : Austin Cancer Centers
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Southwest Regional Cancer Center - North
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology - Midtown
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology North Austin
Connect® MM- The Multiple Myeloma Disease Registry
Bedford :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Bedford : US Oncology - Texas Oncology, PA - Bedford
Connect® MM- The Multiple Myeloma Disease Registry
Bryan : St. Joseph Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Cedar Park : US Oncology - Texas Oncology Cedar Park
Connect® MM- The Multiple Myeloma Disease Registry
College Station : Scott & White Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : Coastal Bend Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : South Texas Institute of Cancer
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : Cancer Specialists Of South Texas, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dallas : Baylor Charles A. Sammons Cancer Center at Dallas
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Dallas :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dallas : Texas Oncology - Dallas Presbyterian
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : Texas Oncology - Medical City Dallas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : US Oncology - Texas Cancer Center at Medical City
Connect® MM- The Multiple Myeloma Disease Registry
Dallas : US Oncology -Texas Oncology, PA - Dallas
Connect® MM- The Multiple Myeloma Disease Registry
Dallas : Mary Crowley Cancer Research Centers
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
El Paso : US Oncology - El Paso Cancer Treatment Ctr
Connect® MM- The Multiple Myeloma Disease Registry
Fort Worth : Texas Oncology - Fort Worth 12th Avenue
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fort Worth : US Oncology - Southwest Forth Worth Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Forth Worth : US Oncology - Texas Oncology, PA - Forth Worth
Connect® MM- The Multiple Myeloma Disease Registry
Ft. Worth :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Garland : US Oncology - Texas Oncology, PA - Garland
Connect® MM- The Multiple Myeloma Disease Registry
Grapevine : US Oncology - Texas Oncology - Grapevine
Connect® MM- The Multiple Myeloma Disease Registry
Houston : MD Anderson Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Houston : MD Anderson Cancer Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Houston : MD Anderson Center
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Houston : MD Anderson Cancer Center/University of Texas Dept.ofMDAndersonCancerCtr(SC)
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Houston :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Houston : UT MD Anderson Cancer Center
Acupuncture for Chemo-Induced Peripheral Neuropathy
Houston : MD Anderson Cancer and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : UT MD Anderson Cancer Center
Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Houston : MD Anderson Cancer Center / University of Texas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : UT MD Anderson Cancer Center
Busulfan Plus Melphalan Versus Melphalan
Houston : UT MD Anderson Cancer Center
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Houston : MD Anderson Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Houston : The Methodist Hospital Research Institute-AOCT
Connect® MM- The Multiple Myeloma Disease Registry
Houston : U T M D Anderson Cancer Center
Dose-escalation Study of Oral CX-4945
Houston : UT MD Anderson Cancer Center Updated
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
Houston : UT MD Anderson Cancer Center
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Houston : UT MD Anderson Cancer Center
MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Houston : University of Texas, MD Anderson Cancer Center
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Houston : Northwest Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Houston : The University Of Texas Md Anderson Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Houston : MD Anderson Cancer Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Houston : Northwest Cancer Center Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Houston : M.D. Anderson Cancer Center
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Houston : MD Anderson
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Houston : Houston VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Irving : Southlake Oncology dba Las Colinas Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Kerrville :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville
Connect® MM- The Multiple Myeloma Disease Registry
Kyle : US Oncology - Texas Oncology - Kyle
Connect® MM- The Multiple Myeloma Disease Registry
Longview : US Oncology - Longview Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lubbock : Joe Arrington Cancer Research and Treatment Center
Connect® MM- The Multiple Myeloma Disease Registry
Midland : US Oncology - Allison Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Odessa : US Oncology - Texas Oncology - Odessa
Connect® MM- The Multiple Myeloma Disease Registry
Plano : US Oncology - North Texas Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Plano : US Oncology - Texas Oncology Plano West Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Round Rock : Texas Oncology - Central Austin Cancer Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Round Rock : US Oncology - Texas Oncology Seton Williamson
Connect® MM- The Multiple Myeloma Disease Registry
Roundrock : US Oncology - Texas Oncology - Round Rock Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
San Antonio : University of Texas Health Science Center
BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
San Antonio : US Oncology - Cancer Care Centers of South Texas
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : US Oncology - HOAST - Medical Dr.
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : South Texas Accelerated Research Therapeutics (START)
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
San Antonio : South Texas Accelerated Research Therapeutics, LLC (START)
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
San Antonio : Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
San Marcos : US Oncology - Texas Oncology - San Marcos
Connect® MM- The Multiple Myeloma Disease Registry
Temple : Scott & White Healthcare Department of Research
Connect® MM- The Multiple Myeloma Disease Registry
Temple : Scott & White Healthcare
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Tyler :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tyler : ETMC dba Blood and Cancer Center - East Texas
Connect® MM- The Multiple Myeloma Disease Registry
Tyler : ETMC dba Tyler Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Waco : US Oncology - Texas Oncology Cancer Care and Research Center
Connect® MM- The Multiple Myeloma Disease Registry
Wichita Falls : US Oncology - Texoma Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Utah
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
American Fork : Central Utah Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Ogden :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Ogden : Northern Utah Associates
Connect® MM- The Multiple Myeloma Disease Registry
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Salt Lake City : Huntsman Cancer Institute
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Salt Lake City : University of Utah - Huntsman Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Salt Lake City : Huntsman Cancer Institute
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Salt Lake City : Huntsman Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Vermont
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Virginia
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Arlington : US Oncology - Arlington Fairfax Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Charlottesville : University of Virginia Health System
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Christiansburg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Fairfax : Virginia Cancer Specialists, PC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fairfax : US Oncology - Fairfax-Northern VA Hem-Onc PC
Connect® MM- The Multiple Myeloma Disease Registry
Fairfax : Virginia Cancer Specialists
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Fredricksburg : Hematology-Oncology Associates Of Fredricksburg, Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gainesville : US Oncology - Fairfax Northern Virginia Hematology-Oncology, PC-Gainesville
Connect® MM- The Multiple Myeloma Disease Registry
Leesburg : US Oncology - Fairfax-Northern Virgina Hem-Onc, PC-Leesburg
Connect® MM- The Multiple Myeloma Disease Registry
Newport News : Peninsula Cancer Institute
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Norfolk :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Richmond : Virginia Commonwealth University
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
Richmond : Virginia Commonwealth University
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Richmond : Massey Cancer Center/Virginia Commonwealth University
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Roanoke :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Salem :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Winchester : US Oncology - Shenandoah Oncology - Winchester
Connect® MM- The Multiple Myeloma Disease Registry
Woodbridge : US Oncology - Fairfax-Northern Virginia Hem-Onc, PC-Woodbridge
Connect® MM- The Multiple Myeloma Disease Registry
Washington
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Bellingham : Peace Health Medical Group
Connect® MM- The Multiple Myeloma Disease Registry
Edmonds : Puget Sound Cancer Centers
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Edmonds : US Oncology - Puget Sound Cancer Center-Edmonds
Connect® MM- The Multiple Myeloma Disease Registry
Everett : Providence Everett Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Kennewick : Columbia Basin Hematology and Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Seattle : Fred Hutchinson Cancer Research
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Seattle : University Of Washington
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Seattle :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Seattle : US Oncology - Puget Sound Cancer Center-Seattle
Connect® MM- The Multiple Myeloma Disease Registry
Seattle : Fred Hutchinson Cancer Research Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Institute
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Spokane :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Spokane : Medical Oncology Associates PS
Connect® MM- The Multiple Myeloma Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Sherman
Connect® MM- The Multiple Myeloma Disease Registry
Spokane Valley : Cancer Care Northwest
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tacoma : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Vancouver :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Walla Walla : Providence St. Mary Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Yakima : Yakima Regional Cancer Care
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge
Connect® MM- The Multiple Myeloma Disease Registry
Yakima :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
BMTCTN0702 - A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma.
Morgantown : West Virginia University - Clinical Trials Research Unit
C16006- An Open-Label, Dose Escalation
Morgantown : West Virginia University - Clinical Trials Research Unit
SNS01-T-001 - Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Huntington : Edwards Comprehensive Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Morgantown : West Virginia University
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Morgantown : West Virginia University - Clinical Trials Research Unit
Connect® MM- The Multiple Myeloma Disease Registry
Morgantown : WVU Mary Babb Randolph Cancer Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Morgantown : West Virginia University Mary Babb Randolf Cancer Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Morgantown : Mary Babb Randolph Cancer Center/WVU
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Wisconsin
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Appleton : Fox Valley Hematology & Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Green Bay : St. Vincent Hospital/Green Bay Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Green Bay : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
La Crosse : Gundersen Lutheran
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
La Crosse : Gundersen Clinic, Ltd
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Madison : University of Wisconsin
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Madison : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Madison : Dean Clinic-Hematology And Oncology
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Milwaukee : Medical College of Wisconsin
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Milwaukee : Froedtert & Medical College of Wisconsin-CLCC
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Milwaukee :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Milwaukee : CMS Water Tower Medical Commons Medical Oncology #100
Connect® MM- The Multiple Myeloma Disease Registry
Milwaukee : MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Milwaukee : Medical College of Wisconsin/Froedtert Hospital
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Milwaukee : Medical College of Wisconsin - Clinical Cancer Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Waukesha : Waukesha Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Waukesha : Waukesha Memorial Hospital (ProHealth Care)
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Wyoming
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Australia
Adelaide : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Adelaide :
Velcade (Bortezomib) Consolidation After Transplant
Box Hill : Box Hill Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Brisbane : Princess Alexandra Hospital - Haematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Camperdown :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
View More »
Camperdown :
Velcade (Bortezomib) Consolidation After Transplant
Canberra : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Darlinghurst : St. Vincent's Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Douglas : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
East Melbourne :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Fitzroy : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Frankston : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Geelong :
Velcade (Bortezomib) Consolidation After Transplant
Greenslopes :
Velcade (Bortezomib) Consolidation After Transplant
Harston : Royal Brisbane and Women's Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Heidelberg :
Velcade (Bortezomib) Consolidation After Transplant
Heidelberg Melbourne : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Herston : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Herston :
Velcade (Bortezomib) Consolidation After Transplant
Hobart : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Liverpool : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Malvern : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Malvern :
Velcade (Bortezomib) Consolidation After Transplant
Melbourne : Peter MacCallum Cancer Centre
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Melbourne : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Melbourne : The Alfred Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Nedlands : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Nedlands :
Velcade (Bortezomib) Consolidation After Transplant
Newcastle :
Velcade (Bortezomib) Consolidation After Transplant
Nsw 2298 : Calvary Mater Newcastle
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Parkville : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Perth : Royal Perth Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Perth : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Prahran : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Prahran :
Velcade (Bortezomib) Consolidation After Transplant
Randwick :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
South Brisbane : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
South Brisbane : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Sydney :
Velcade (Bortezomib) Consolidation After Transplant
Tweed Heads : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Waratah : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Westmead : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Westmead N/A :
Velcade (Bortezomib) Consolidation After Transplant
Wodonga : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Woodville South : The Queen Elizabeth Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Woodville South :
Velcade (Bortezomib) Consolidation After Transplant
Woolloongabba :
Velcade (Bortezomib) Consolidation After Transplant
Austria
Graz :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Graz : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Innsbruck :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Innsbruck : Medical University Innsbruck, Division of Hematology and Oncology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Innsbruck : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
Linz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rankweil : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Salzburg : University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Vienna : AKH Vienna
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Wilhelminenspital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Wilhelminenspital, Department of Medicine I, Center of Oncology and Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Wels : Klinikum Wels-Grieskirchen GmbH
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Wels : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Wien : Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Wien : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Belgium
Andtwerpen : ZNA AZ Stuivenberg
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Antwerpen :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Antwerpen :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Antwerpen : Lange Beeldekensstraat
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Brussel : Universitair Ziekenhuis Brussel
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
View More »
Brussels : UCL Saint Luc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brussels :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Brussels :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Brussels : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brussles : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Charleroi : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Edegem-Antwerp : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gent :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Gent :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Haine St Paul : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Leuven : UZ Gasthuisberg
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Leuven : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Liege : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mons : CHU Ambroise Pare
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Roeselare : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Yvoir : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brazil
Bulgaria
Plovdiv : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Sofia : Tokuda Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Canada
Barrie : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Burnaby : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Calgary : Tom Baker Cancer Centre
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Calgary : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Calgary : Tom Baker Cancer Centre
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
View More »
Edmonton : Cross Cancer Centre
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Edmonton : Cross Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Edmonton : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Halifax : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Halifax : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Laval : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
London : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Moncton : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Montral : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Montreal : Royal Victoria Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Montreal :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Newmarket : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ontario : London Health Sciences Centre
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ontario : The Ottawa Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Quebec : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Quebec : CHA/Québec-Hôpital Enfant-Jésus
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Quebec City :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Saint John : Saint John Regional Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Saint John : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Saskatoon : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Toronto : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Toronto : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Toronto : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Toronto : University Health Network, Princess Margaret Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Vancouver : Vancouver General Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Vancouver : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Vancouver : Vancouver General Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Windsor : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Windsor : Windsor Regional Cancer Program
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Winnipeg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
China
Beijing : Beijing Clinical Service Center
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Tianjin : Hematologic Hospital of Chinese Academy of Medical Sciences
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
Croatia
Zagreb :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Czech Republic
Brno : Fakultni nemocnice Ostrava
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brno :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Brno : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Brno : Fakultni nemocnice Brno
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Brno : Fakultni nemocnice Brno
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
View More »
Hradec Kralove : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Olomouc : Fakultni Nemocnice Olomouc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Olomouc : Fakultni nemocnice Olomouc
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ostrava : Fakultni nemocnice Ostrava
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ostrava-Poruba : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Prague :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Prague : Všeobecná fakultní nemocnice v Praze
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Praha 10 : Fakultni Nemocnice Kralovske Vinohrady
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Praha 10 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Praha 10 : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Sokolska : Fakultni nemocnice Hradec Kralove
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Srobarova : Fakultni nemocnice Kralovske Vinohrady
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Denmark
Copenhagen : Rigshospitalet Clinic of Hematology L4042
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Holstebro N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Odense :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vejle : Vejle Sygehus
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Vejle : Vejle Hospital
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Estonia
Tallinn N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Tartu :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Finland
Helsinki : Helsinki University Hospital Hemat Dept
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
France
Aix-en-provence : CH du Pays D'Aix
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
AMIENS cedex 1 : CHRU - Hôpital Sud Amiens
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
ANGERS cedex 01 : CHU d'Angers
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Argenteuil : Centre Hospitalier Argenteuil Victor Dupouy
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Avignon : Centre Hospitalier H.Duffaut
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
View More »
Avignon Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bayonne : Centre Hospitalier de la côte basque
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Bayonne : Centre Hospitalier de la côte basque - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Besançon : Hôpital Jean Minjoz
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Blois : Centre Hospitalier de Blois
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Blois Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bobigny : Hôpital Avicenne
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Bordeaux :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Bordeaux : Polyclinique Bordeaux Nord Aquitaine
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Bordeaux Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Brest : Hôpital A.Morvan
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Brest Cedex 2 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Caen :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Caen : Chru Caen
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Caen : CHU Caen Côte de Nacre
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Cedex : Centre Hospitalier de lo Cote Baque
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Cedex : Centre Hospitalier Lyon-Sud
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Cergy-Pontoise : CH René Dubos
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Chalon-sur-saone : Centre Hospitalier William Morey
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Chambéry : CH Chambéry
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Clamart cedex : Hôpital Antoine Béclère
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Clamart cedex : Hôpital d'instruction des armées Percy
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Clermont - Ferrand : Pole Santé République
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Clermont Ferrand : CHU Estaing
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Clermont Ferrand Cedex 2 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Clermont-Ferrand : CHU d'Estaing
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Corbeil Essonne : Centre Hospitalier Sud Francilien
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Corbeil-Essonnes : CH Sud Francilien
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Créteil : CHU Henri Mondor
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Dijon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Dijon : CHU DIJON, Hôpital d'Enfants
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Dijon : CHRU Dijon
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Dunkerque : Centre Hospitalier Général - Dunkerque
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Grenoble : CHRU, Hôpital A.Michallon
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Grenoble : Hôpital A.Michallon
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Grenoble Cedex 9 : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
La Roche sur Yon cedex : Centre hospitalier départemental - La Roche sur Yon cedex
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Le Coudray : CH de Chartres - Hôpital Louis Pasteur
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Le Mans : CH Le Mans
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Le Mans : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Le Mans : Centre hospitalier Le Mans
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Le Mans : Centre Jean Bernard
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Le Mans : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Le Mans Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Le Mans Cedex 9 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Lille : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lille : Chru Lille
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Lille : CHRU - Hôpital Claude Huriez
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Lille : CHRU de Lille - Service des maladies du sang
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Lille Cedex :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Lille cedex : CHRU de Lille, Hopital Huriez
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Lille Cedex : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Limoges : Hôpital Universitaire Dupuytren
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Limoges : CHU de Limoges
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Lorient : Centre hospitalier Bodelio
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Lyon :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Lyon : CHU - Hôpital Edouard Herriot
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Lyon : Centre Léon Bérard
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Marseille : Hôpital Ambroise Paré
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Marseille :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Marseille : Institut Paoli Calmette,
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Marseille : Institut Paoli Calmettes
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Marseille cedex 5 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Meaux : CH Meaux
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Montpellier :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nantes :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Nantes : Hôtel-Dieu
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Nantes : Hôpital de l'Hôtel Dieu
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Nantes : CHRU, Hôtel Dieu
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Nantes : Centre Catherine de Sienne
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Nantes : CHRU - Hôtel Dieu
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Nantes : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Nantes Cedex 1 :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Nantes Cedex 1 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Nantes N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nice Cedex 3 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
NICE cedex 3 : Hôpital Archet 1
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Nice cedex 3 : Hôpital de l'Archet
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Nimes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Nîmes :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nîmes Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nîmes Cédex 9 : Groupe Hospitalo-Universitaire Carémeau
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Paris : Hôpital Saint Louis
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris : Hopital Saint Antoine
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Paris : Hopital Saint Louis - Service d'Immuno-Hematologie
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Paris : CHU - Hôpital St Antoine,
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Paris : Hôpital Saint-Louis
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Paris : Institut Curie
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Paris : Hôpital Cochin
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Paris : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Paris : CHU Saint Antoine - Service des maladies du sang
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Paris : Hôpital Saint Louis - Immuno-hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
PARIS cedex 10 : Hôpital Saint-Louis
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Paris Cedex 12 : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Paris cedex 12 : Hôpital St-Antoine
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Perpignan : Centre Hospitalier Saint Jean
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Perpignan : CH Saint Jean
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Perpignan Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Pessac : CHRU - Hôpital du Haut Lévêque
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Pessac Cedex : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pierre - Bénite cedex : Centre Hospitalier Lyon sud
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Pierre Benite : Centre Hospitalier Lyon Sud -1
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Pierre Benite : Centre Hospitalier Lyon Sud -2
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Pierre-Benite : Centre Hospitalier Lyon sud - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Poitiers : CHRU - Hôpital Jean Bernard
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Pontoise :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Pringy : Centre Hospitalier de la région d'Annecy
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Reims : Hôpital R.Debré
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Rennes :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Rennes : CHRU RENNES 2, Hôpital Pontchaillou
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Rennes : CHRU - Hôpital Sud
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Rennes : CHRU - Hôpital de Pontchaillou
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Rouen : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Rouen : Centre Henri Becquerel
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Rouen Cedex : Centre Henri Becquerel
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Saint Herblain :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
St Brieuc Cedex 1 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
St Cloud : Centre René Huguenin
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
St-Brieuc cedex 1 : Centre Hospitalier Yves le Foll
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
St-priest-en-jarez : Institut de Cancérologie de la Loire
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Strasbourg : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Strasbourg : Hôpitaux Universitaires de Strasbourg
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Toulouse :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Toulouse : University Hospital of Toulouse, Purpan
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Toulouse : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Toulouse Cedex : Institut Claudius Régaud
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Tours :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Tours :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Tours : CHRU - Hôpital Bretonneau
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Tours : Hôpital Bretonneau - Hématologie & Thérapie cellulaire
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Troyes Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Valence : Centre Hospitalier de Valence
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Vandoeuvre : CHRU, Hôpitaux de Brabois
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Vandoeuvre cedex : Hôpitaux de Brabois
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Vandoeuvre Les Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Vandoeuvre Les Nancy : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Vandoeuvre-les-Nancy : CHU Nancy - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Vannes cedex : CH Bretagne Atlantique Vannes et Auray
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Villefranche Sur Saone Cedex : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Villejuif :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Villejuif :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Villejuif Cedex : Institut Gustave Roussy, Dept. of Medicine
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Germany
Aschaffenburg : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Berlin :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Berlin : MediOnko-Institut GRR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Onkoplan GmbH/ Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : "Medizinisches Versorgungszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
View More »
Berlin : Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bonn : "Praxiskooperation Bonn-Euskirchen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Borken : "Facharzt für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Brandenburg : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Chemnitz : Poliklinik GmbH Chemnitz
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Chemnitz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Cottbus : Fachärztin für Innere Medizin / Hämatologie / Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Dresden : "Facharzt für Innere Medizin/
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Dresden : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Eisenach : "Facharzt für Innere Medizin Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Flensburg : Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Frankenthal : Internist / Hämatologe / Intern. Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Freiburg : Universitätsklinikum Freiburg, Abteilung für Innere Medizin I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Freiburg : University Medical Center Freiburg
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
Garbsen : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Gosiar : Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Groitzsch : Medizinisches Studien- und Dokumentationszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halberstadt : FA für Innere Medizin - Hämatologie - Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Hamm : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Hannover : MediProjekt Ges. f. Medizinstatistik und Projektentwicklung
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Heidelberg : Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum, Im Neuenheimer Feld 410
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Heidelberg :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Heidelberg : University Hospital of Heidelberg, Department V
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
Heidelberg : Department of Internal Medicine V
Exploratory Study on POL6326 in Stem Cell Mobilization
Heidelberg : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Heidenheim : ODZ-Petersen GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Herne : DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Jena : "Medizinisches Versorgungszentrum MP Saaletal GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Jena : Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Jena : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Kiel : Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Koeln :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Koln : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Krefeld : OnkoMed GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Leipzig : Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik II
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Leipzig : University of Leipzig
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Lübeck : Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Mainz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mannheim :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Munchen : Facharzle fur Innere Medizin - Hamatologie u. Intemistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen : Facharzte fur Innere Medizin - Hamatologie u. Intermistische Onkologie - Bluttransfusionswesen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
München : III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Munich : Klinikum rechts der Isar/ Studien / III. Med. Klinik/ Ismaninger Str. 22
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Munster : Gemeinschaftspraxis für Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munster : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Neuss : Tumorzentrum Niederrhein GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Überörtliche Gemeinschaftspraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Facharzt für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Offenbach : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Oldenburg : Klinikum Oldenburg GmbH, Klinik für Innere Medizin II
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Olpe : Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oranienburg : Fachärztin für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Osnabruck : Paracelsusklinik
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Paradiese : Medizinisches Versorgungszentrum GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : FA f. Innere Medizin, Onkologie und Endokrinologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Plauen : FA für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Remscheid : Facharzt für Innere Medizin - Medikamentöse Tumortheraphie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rodgau : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Schoenebeck : FA fur Innere Medizin - Hamatologie - Intermistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Stralsund : "FA f. Frauenheilkunde und Geburtshilfe SP Gynakologische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Stuttgart : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tübingen : Universitätsklinikum Tübingen - Medizinische Klinik und Poliklinik - Abteilung II
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Tuebingen : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ulm : Universitätsklinikum Ulm,Klinik für Innere Medizin III
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Ulm : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ulm : Universitätsklinikum Ulm - Klinik fur Innere Medizin III
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Velbert : Praxis fur Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Verden : Facharzt für Innere Medizin Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Villingen-Schwenningen : Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
VS-Villingen : Onkologische Schwerpunktpraxis Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Wuerzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Würzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Oberdürrbacher Straße 6
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Greece
Ampelokipoi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Athens : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Athens : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Heraklion : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Ioannina : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Larissa : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Patra : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Patras : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Thessaloniki : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hong Kong
Shatin, N.T. : Department of Clinical Oncology, Prince of Wales Hospital
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Hungary
Budapest :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Budapest : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Budapest : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Debrecen : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Gyula : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Kaposvar : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kaposvar : Somogy Megyei Kaposi Mor Oktato Korhaz
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Pécs N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Szeged :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Szeged : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Szombathely :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ireland
Co Galway : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dublin : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Dublin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dublin 24 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dublin 7 : Keryx / AOI Pharmaceuticals Investigative Site
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
View More »
Dublin 8 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dublin 9 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Galway :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Galway : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Limerick :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Sligo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tullamore :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Waterford :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Israel
Afula :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Afula : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ashkelon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Ashkelon :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Ashkelon : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
Beer Sheva :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Haifa :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Haifa :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Haifa : Rambam Health Care Campus
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Jerusalem :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Jerusalem : Hadassah University Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Jerusalem : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Kfar Saba :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Naharia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Nahariya :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Nahariya : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Petach Tikva :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Petach Tikva :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Petah Tikva :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Petah Tikva : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Petah-Tikva :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ramat Gan :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ramat Gan : Sheba MC
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
Rehovot :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Rehovot : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tel Aviv :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tel Aviv : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tel-Hashomer :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Zerifin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Italy
Ancona : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ancona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ancona : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Bergamo : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
Bologna : Istituto de Ematologia ed Oncologia Medica
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Bologna : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bologna : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bologna : Università degli Studi di Bologna - Policlinico S. Orsola - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Bolzano : Division of Hematology and CBMT
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Brescia : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Catania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Catania : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Firenze : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Firenze : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Firenze : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Firenze : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Genova : University Hospital San Martino, Department of Hematology and Oncology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Genova : IRCCS Azienda Ospedaliera Universitaria San Martino
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Genova : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Genova : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Meldola : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Milano : Niguarda Ca'Granda Hospital, Department of Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Milano : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Milano : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Modena : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Monza : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Napoli : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Napoli : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Napoli : Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Novara : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Novara : Azienda Ospedaliera Universitaria Maggiore
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Palermo : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Pescara : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pescara : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Piacenza : Ospedale Guglielmo da Saliceto - hematooncology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Pisa : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ravenna : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ravenna : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Rimini : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rimini : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Roma : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Roma : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Roma : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Roma : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Rome : Sapienza University of Rome, Department of Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Rome : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Torino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Torino : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Torino : Azienda Ospedaliera Universitaria San Giovanni
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Torino : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Torino : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Torino : A.O.U. San Giovanni Battista - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Vimercate MB : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Japan
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Akita-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fukuoka : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Isehara : Celgene Trial Site
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
View More »
Kamogawa-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Kawagoe-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kumamoto-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kyoto :
Efficacy Study of SyB L-0501 for Patients With Multiple Myeloma
Kyoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Kyoto-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maebashi-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Nagoya : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Nagoya :
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Nagoya-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ogaki-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Okayama-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Shibukawa-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Shibuya-ku : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tokushima-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tokyo : Celgene Trial Site
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Tokyo :
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Toyama-shi : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Korea, Republic of
Daejeon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Daejeon : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Gwangju : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hwsun-eup, Hwasun-gun : Je-Jung Lee
TCD Followed by autoSCT for Newly Diagnosed MM Patients
View More »
Incheon : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Inchon : Gachon University Gil Hospital
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Seoul :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Seoul :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Seoul : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Seoul : Seoul National University Hospital
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Seoul : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Latvia
Riga :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lithuania
Klaipeda :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vilnius :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Macedonia, The Former Yugoslav Republic of
Skopje :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Malaysia
Kuching : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Mexico
Netherlands
Amsterdam : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Amsterdam : VU Medical Center
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Nieuwegein : Antonius Ziekenhuis Nieuwegein
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Rotterdam : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Utrecht : Uni.Med Center Utrecht
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
View More »
Utrecht : UMC Utrecht
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
New Zealand
Auckland : Middlemore Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Auckland : Auckland City Hospital, Auckland District Health Board
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Auckland : Middlemore Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Auckland City : North Shore Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Christchurch : Canterbury Health Laboratories
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
View More »
Christchurch : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Christchurch : Christchurch Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Christchurch : Canterbury Health Laboratories
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Grafton, Auckland : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hamilton : Waikato Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Newtown, Wellington : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Palmerston North : Palmerston North Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Wellington : Wellington Regional Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Poland
Bialystok :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bialystok : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brzozow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bytom :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Chorzow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
View More »
Chorzow : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gdansk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Katowice :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Legnica :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lublin :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lublin : SPSK1 Klinika Hematologii
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Lublin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Opole :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Poznan :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Poznan : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rzeszow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Slupsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Warsaw : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Warszawa :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Warszawa : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Warszawa : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Warszawa Poland :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Wroclaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Wroclaw :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Wroclaw : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Zamosc : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Zamosc :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Portugal
Porto : Instituto Portugues de Oncologia do Porto Francisc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Puerto Rico
Ponce : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
San Juan : Auxilio Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Romania
Brasov : Spitalul Judetean
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Brasov : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bucaresti : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bucharest : "Coltea" Clinical Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
View More »
Bucuresti : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Cluj-Napoca : Institutul Oncologic
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Lasi : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Timisoara : Oncomed
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Russian Federation
Krasnodar :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Krasnogorsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Moscow :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Nizhny Novgorod : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Petrozavodsk : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Petrozavodsk : State Healthcare Institution "Republican Hospital named after V.A. Baranov"
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Podolsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Saint Petersburg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Saint-Petersburg :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Samara :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Samara : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Saransk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
St Petersburg :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
St. Petersburg : Federal State Institution "Russian Scientific and Research Institute of Hematology and Transfusiology" of Federal Medical Biological Agency
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Ulyanovsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vologda :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Singapore
Singapore : Novartis Investigative Site
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Singapore : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Singapore : National University Hospital (Cancer Institute)
Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma
Singapore : National University Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Slovakia
Kosice :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Slovenia
Ljubljana :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Spain
Alcalá de Henares : Hospital Principe de Asturias
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Alcorcón : Fundación Hospital Alcorcón
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Badalona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Badalona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Badalona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
View More »
Badalona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Badalona : Hospital Germans Trias i Pujol
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Badalona : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Badalona : Hospital de Badalona Germans Trias i Pujol
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Badalona : Hospital Germans Trias i Pujol - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Badalona-Barcelona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Barcelona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcelona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Barcelona :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Barcelona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Barcelona : Institut català d'Oncología
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Barcelona : Hospital Clínic
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Barcelona : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Barcelona : Hospital Clinic i Provincial de Barcelona
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Barcelona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Barcelona : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Barcelona : Hospital Universitari Germans I Pujol
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Barcelona : Hospital Clínic i Provincial de Barcelona
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Barcelona : Hospital de la Santa Creu i Sant Pau
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : Hospital del Mar
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : ICO - Duran i Reynals, Hospitalet de Llobregat
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : H. Vall d'Hebron, Barcelona
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : Hospital Clinic i Provincial de Barcelona
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcleona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcleona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Bilbao : Hospital de Cruces
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cáceres : Complejo Hospitalario de Cáceres
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cádiz : Hospital Puerta del Mar
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Castellón : Hospital General de Castellón
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Ciudad Real : Hospital General
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cuenca : Hospital Virgen de la Luz
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Donostia : Hospital Donostia
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Gandía : Hospital Francesc Borja
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Girona : ICO - Josep Trueta
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Guadalajara : Hospital General de Guadalajara
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Jerez de la Frontera : H. de Jerez
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
La Laguna :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Leon : Complejo Hospitalario León
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
L'Hospitalet De Llobregat :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Madrid : Hospital General Universitario Gregorio Marañon
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Madrid :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Madrid :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Madrid :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Madrid : MD Anderson Internacional
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Universitario de la Princesa
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital 12 de Octubre
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Clínico San Carlos
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Universitario Ramón y Cajal
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Madrid : Centro Integral Oncologico Clara Campal
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Madrid : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Madrid : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Madrid : Hospital Universitario de La Princesa
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Madrid : Hospital de la Princesa
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de Madrid, S.A.- Norte Hospital General
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital 12 de Octubre. Madrid
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Infanta Leonor
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : MD Anderson
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Universitario Gregorio Marañón
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital del Tajo
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de Fuenlabrada
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Clinico San Carlos
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Infanta Sofia
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital la Paz
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Ramón y Cajal
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Severo Ochoa
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Clínica Puerta de Hierro
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de La Princesa - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Málaga : Hospital Universitario Virgen de la Victoria
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Málaga : Complejo Hospital Costa del Sol
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Málaga : Hospital Nuestra Señora de Valme
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Manresa : Althaia
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Murcia : Hospital General Morales Messeguer
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Murcia : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Murcia : Hospital General Univeristario Morales Messeguer
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Murcia : Hospital Virgen de la Arrixaca
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Navarra : Hospital de la Diputación de Navarra
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Ourense : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Oviedo : Hospital Universitario Central de Asturias
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Palma de Gran Canaria : Hospital de Gran Canaria Doctor Negrín
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Palma de Mallorca : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Palma de Mallorca : H. Son Llatzer
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Palma de Mallorca : Complejo Asistencial Son Dureta
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Pamplona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Pamplona : Hospital Virgen del Camino
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Pamplona : Clínica Universitaria de Navarra
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Sabadell : Corporació Sanitaria Parc Taulí
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Salamanca : Novartis Investigative Site
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Salamanca :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Salamanca :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Salamanca :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Salamanca : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Salamanca : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Salamanca : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Salamanca : Hospital Universitario de Salamanca
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Salamanca : Hospital Clínico de Salamanca
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Salamanca : Hospital Universitario de Salamanca
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
San Sebastián : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
San Sebastian : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
San Sebastian : Hospital Donosti
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Santander : Hoaspital Marqués de Valdecilla
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Santiago Compostela : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Santiago de Compostela : Complejo Hospitalario Universitario de Santiago
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Segovia : Hospital General de Segovia
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Sevilla : Hospital Universitario Virgen del Rocío
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Sevilla : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Sevilla : Hospital Universitario Virgen del Rocio
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Sevilla : Complejo Hospitalario Regional Virgen del Rocío
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Seville : Servicio de Oncologia Medica Sala de Investigación
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Tarragona : Hospital Joan XXIII
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Tenerife : Hospital Universitario de Canarias
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Toledo : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Toledo : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Toledo : Hospital Virgen de la Salud
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Toledo : Hospital Nuestra Señora del Prado
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Valencia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Valencia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Valencia :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Valencia :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Valencia : Hospital Universitario La Fe
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Valencia : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Valencia : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Valencia : Hospital Universitario Dr. Peset
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Valencia : Hospital La Fe
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Valencia : Hospital Arnau de Vilanova
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Valencia : Hospital Clínico de Valencia.
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Vitoria : Hospital Txagorritxu
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Zamora : Hospital Virgen de la Concha
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Zaragoza :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Zaragoza : Hospital Clinico Universitario Lozano Blesa
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Zaragoza : Local Institution Updated
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Zaragoza : Miguel Servet
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Zaragoza : Hospital Clinico Lozano Blesa
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Sweden
Goteborg : Sahlgrenska Universitetssjukhuset
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Göteborg :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Göteborg :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Linköping N/A :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Linköping N/A :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
View More »
Lund : Skånes Universitetssjukhus- Lund
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lund : Skane University Hospital
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Stockholm : Karolinska Universitetssjukhuset i Huddinge
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Stockholm : Karolinska universitetssjukhuset Solna
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Stockholm :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Stockholm :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Stockholm : Karolinska University Hospital - Huddinge
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Switzerland
Basel : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Bern : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Chur : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Genolier : IMO Clinique de Genolier
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
St Gallen : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
St. Gallen : Kantonsspital St. Gallen
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Zurich : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Zurich : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Taiwan
Neihu Taipei : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Taichung : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Taichung : China Medical University Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Tainan : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tainan : National Cheng Kung University Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
View More »
Taipei : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Taipei : Research Site
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Taipei : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Turkey
Adana : Baskent University School of Medicine Education and Research Hospital, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Ankara :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ankara : Ankara University School of Medicine, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Ankara : Ankara Numune Education and Research Hospital,Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Ankara : Gazi University School of Medicine, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
View More »
Ankara : Hacettepe University School of Medicine, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Antalya : Akdeniz University School of Medicine , Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Bursa :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bursa : Uludag University School of Medicine, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Eskisehir : Osmangazi University School of Medicine , Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Istanbul : Marmara University School of Medicine, Hematology Department
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Izmir : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Izmir :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Kayseri :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Melikgazi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Samsun :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Sihhiye : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Ukraine
Kherson :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Zhitomir :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
United Kingdom
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Birmingham : University Hospital Birmingham
European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy
Bournemouth : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Bournemouth : Royal Bournemouth General Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Cambridge : Addenbrooke's Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
View More »
Glasgow :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Headington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Liverpool : Dept of Haematology, University of Liverpool
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
London :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
London : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
London :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
London : The Royal Free Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
London : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
London : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
London : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
London : Centre for Experimental Cancer Medicine/Bart's Cancer Institute
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
London : University College London
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
London : King's College Hospital - Haematology Clinical Trials
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Manchester :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Manchester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Manchester : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Oxford : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Rotherham : The Rotherham NHS Foundation Trust - Dept. of Haematology
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Sutton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Sutton :
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
United Kingdom : 135 sites UK wide
Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
